Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | HHAT | Q5VTY9 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881329 | 0.80 | GID4 (0.32) | LMNAGID4TAAR1KEAP1HHAT | |
| SCHEMBL13117935 | 0.80 | GID4 (0.32) | LMNAGID4TAAR1KEAP1HHAT | |
| SCHEMBL13881165 | 0.80 | GID4 (0.32) | LMNAGID4TAAR1KEAP1HHAT | |
| SCHEMBL13881339 | 0.80 | GID4 (0.32) | LMNAGID4TAAR1KEAP1HHAT | |
| SCHEMBL16519797 | 0.77 | GRIN2B (0.42) | GRIN2BLMNADRD3DRD2GID4 | |
| SCHEMBL4616762 | 0.77 | GRIN2B (0.39) | GRIN2BLMNADRD3DRD2GID4 | |
| SCHEMBL6899478 | 0.77 | GRIN2B (0.39) | GRIN2BLMNADRD3DRD2GID4 | |
| SCHEMBL22458038 | 0.75 | — | — | |
| SCHEMBL22458036 | 0.75 | — | — | |
| SCHEMBL1747061 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011070131-A1 | 5-AMINO- 4-HYDROXYPENTOYL AMIDES | TIBOTEC PHARMACEUTICALS (IE) | 2011-06-16 | — | — | WO | disclosed |
| US-7807677-B2 | HIV protease inhibitors | MEDIVIR AB (SE) | 2010-10-05 | — | — | US | disclosed |
| US-7807677-B2 | HIV protease inhibitors | MEDIVIR AB (SE) | 2010-10-05 | — | — | US | disclosed |
| EP-1851193-B1 | HIV PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080249102-A1 | Hiv Protease Inhibitors | MEDIVIR AB (SE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249102-A1 | Hiv Protease Inhibitors | MEDIVIR AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249102-A1 | Hiv Protease Inhibitors | SERPINB1, ANPEP, XPNPEP1 | GRIN2B 4004/4885LMNA 534/4885DRD3 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.